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Abstract  The  recently  emergent  ﬁeld  of  Nanotechnology  involves  the  production  and  use  of
structures  at  the  nanoscale.  Research  at  atomic,  molecular  or  macromolecular  levels,  has
led to  new  materials,  systems  and  structures  on  a  scale  consisting  of  particles  less  than
100 nm  and  showing  unique  and  unusual  physical,  chemical  and  biological  properties,  which  has
enabled new  applications  in  diverse  ﬁelds,  creating  a  multimillion-dollar  high-tech  industry.
Nanotechnologies  have  a  wide  variety  of  uses  from  nanomedicine,  consumer  goods,  electron-
ics, communications  and  computing  to  environmental  applications,  efﬁcient  energy  sources,
agriculture,  water  puriﬁcation,  textiles,  and  aerospace  industry,  among  many  others.
The different  characteristics  of  nanoparticles  such  as  size,  shape,  surface  charge,  chemical
properties,  solubility  and  degree  of  agglomeration  will  determine  their  effects  on  biological
systems  and  human  health,  and  the  likelihood  of  respiratory  hazards.  There  are  a  number  of
new studies  about  the  potential  occupational  and  environmental  effects  of  nanoparticles  and
general precautionary  measures  are  now  fully  justiﬁed.
Adverse  respiratory  effects  include  multifocal  granulomas,  peribronchial  inﬂammation,  pro-
gressive interstitial  ﬁbrosis,  chronic  inﬂammatory  responses,  collagen  deposition  and  oxidative
stress.
The authors  present  an  overview  of  the  most  important  studies  about  respiratory  nanotoxicol-
ogy and  the  effects  of  nanoparticles  and  engineered  nanomaterials  on  the  respiratory  system.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Resumo  O  campo  recentemente  emergente  da  nanotecnologia  envolve  a  produc¸ão  e  o  uso
Nanotubos;
Fulerenos;
Pulmão;
Toxicologia
de estruturas  em  nanoescala.  A  pesquisa  a  níveis  atómicos,  moleculares  e  macro  molecu-
lares conduziu  a  novos  materiais,  sistemas  e  estruturas  numa  escala  constituída  por  partículas
menores que  100  nm,  apresentando  propriedades  físicas,  químicas  e  biológicas  únicas  e  inco-
muns, o  que  tem  permitido  novas  aplicac¸ões  em  diversos  campos,  criando  uma  indústria  de
alta tecnologia  multimilionária.  As  nanotecnologias  têm  uma  vasta  variedade  de  usos,  desde  a
nano medicina,  bens  de  consumo,  eletrónica,  comunicac¸ões  e  informática,  até  às  aplicac¸ões
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ambientais,  fontes  de  eﬁciência  energética,  agricultura,  puriﬁcac¸ão  de  água,  têxteis  e  indústria
aeroespacial,  entre  muitos  outros.
As diferentes  características  das  nanopartículas,  tais  como  tamanho,  forma,  carga  de  superfí-
cie, propriedades  químicas,  solubilidade  e  grau  de  aglomerac¸ão,  determinarão  os  efeitos  sobre
os sistemas  biológicos  e  na  saúde  humana  e  a  probabilidade  de  riscos  respiratórios.  Existem
alguns novos  estudos  sobre  os  potenciais  efeitos  ocupacionais  e  ambientais  das  nanopartículas,
sendo totalmente  justiﬁcadas  as  medidas  gerais  de  precauc¸ão.
Os efeitos  respiratórios  adversos  incluem  granulomas  multifocais,  inﬂamac¸ão  peribrônquica,
ﬁbrose intersticial  progressiva,  respostas  inﬂamatórias  crónicas,  deposic¸ão  de  colagénio  e  stress
oxidativo.
Os autores  apresentam  um  resumo  dos  mais  importantes  estudos  sobre  nanotoxicologia
respiratória  e  dos  efeitos  das  nanopartículas  e  dos  nanomateriais  artiﬁciais  sobre  o  sistema
respiratório.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
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Introduction
The  second  half  of  the  XX  Century  saw  the  emergence  of  a
truly  revolutionary  era  of  nanotechnology.
The  development  of  new  materials,  systems  and
structures  through  research  at  atomic,  molecular,  or  macro-
molecular  levels  has  enabled  new  applications.
The  nanoscale  is  typically  a  scale  of  matter  under  100  nm.
According  to  several  authors,  unique  and  unusual  physi-
cal,  chemical,  and  biological  properties  can  be  seen  at  this
dimensional  level.
Nanotechnology  involves  imaging,  measuring,  modeling,
and  manipulating  matter  at  this  scale.  Some  of  the  most
promising  uses  of  these  technologies  have  emerged  in
some  fundamental  sectors,  such  as  energy,  communications,
water  puriﬁcation,  pollution  reduction  and  environmental
progress,  improved  materials  and  new  products,  medical
and  biomedical  applications.1,2
Besides  industrial  and  household  uses,  nanoparticles
(NPs)  can  be  used  in  Medicine  (creating  the  new  ﬁeld  of
nanomedicine)  for  cancer  treatment,  infectious  diseases,
immunization  purposes  and  diagnostic  procedures  with  new
imaging  sensors  and  agents.3,4
As  nanotechnology  penetrates  the  marketplace  and
attracts  attention,  the  public  is  starting  to  develop  opinions
about  it.  Those  opinions  will  shape  the  market  for  consumer
goods  using  these  new  technologies.5
Nanotechnology  is  a  sector  of  high-tech  industry  that  has
already  created  a  multibillion  $US  market,  and  is  widely
expected  to  grow  to  1  trillion  (1018)  US  dollars  by  2015.6
Nanotechnology  research  and  development  can  integrate
the  nanoscale  structures  into  larger  material  components,
systems,  and  architectures.7
The  majority  of  the  NPs  currently  in  use  today  have  been
made  from  transition  metals,  silicon,  different  forms  of  car-
bon  (carbon  nanotubes;  fullerenes),  and  metal  oxides  (such
as  zinc  dioxide  and  titanium  dioxide).
In  sensu  lato, inorganic  nanoparticles  do  not  contain  car-
bon  molecules;  carbon  nanotubes  and  carbon  fullerenes  are
usually  addressed  as  organic  nanoparticles.  But  it  must  be
stated  that,  strictly  from  a  chemical  point  of  view,  these
forms  containing  pure  carbon  molecules  without  bonds  to
hydrogen,  constitute  allotropes  of  carbon  and  are  part  of
what  is  now  known  as  the  Inorganic  Chemistry  of  Carbon.
p
s
eNew  applications  are  constantly  emerging.  The  Nano-
echnology  Consumer  Products  Inventory,  kept  by  the
oodrow  Wilson  Institute,  listed  over  1317  products  or  prod-
ct  lines  as  of  April  2012.8
Nanomaterials  vary  widely  in  terms  of  their  composition,
roperties,  and  uses.  Common  products  include  cosmetics
nd  personal  care  products,  wound  dressing  pads,  pregnancy
ests,  toothpaste,  food  supplements  and  food  storage,  appli-
nces,  clothing,  coatings,  electronics  and  computers  and
porting  goods.5
With  the  increasing  technological  complexity  of  nano-
echnology,  several  generations  of  NPs  can  be  reported:
First  generation  ∼2001:  Passive  nanostructures  (nano-
tructured  coatings,  nanoparticles,  nanostructured  metals,
olymers,  ceramics,  catalysts,  composites,  displays).
Second  generation  ∼2007:  Active  nanostructures  (tran-
istors,  ampliﬁers,  targeted  drugs  and  chemicals,  actuators,
daptive  structures,  sensors,  diagnostic  assays,  fuel  cells,
olar  cells,  high  performance  nanocomposites,  ceramics,
etals).
Third  generation  ∼2010:  3-D  nanosystems  and  systems
f  nanosystems  (various  assembly  techniques,  networking  at
he  nanoscale  and  new  architectures,  biomimetic  materials,
ovel  therapeutics/targeted  drug  delivery).
Fourth  generation  ∼2015:  Molecular  nanosystems
molecular  devices  ‘‘by  design’’,  atomic  design,  emerging
unctions).9
The  expression  ‘‘nanoparticle’’  is  commonly  used  to
escribe  engineered  structures  with  diameters  of  <100  nm,
hat  are  created  by  chemical  and/or  physical  processes,
ith  very  characteristic  properties  usually  not  present  at
 macro-scale  level.10
Reducing  the  size  of  a  particle  increases  the  ratio  of
urface  area  to  mass.  Because  the  reactive  portion  of  the
article  is  on  the  surface,  increasing  the  relative  surface
rea  will  increase  reactivity  of  a  given  amount  of  material.
lso,  at  the  nanoscale,  both  classical  physics  and  quan-
um  physics  can  direct  the  behaviour  of  a  particle.  The
nﬂuence  of  quantum  effects  can  change  important  mate-
ial  properties,  such  as  optical,  magnetic,  and  electrical
roperties.5
NPs  may  be  suspended  in  a  gas  (as  a  nanoaerosol),
uspended  in  a  liquid  (as  a colloid  or  nano-hydrosol),  or
mbedded  in  a matrix  (as  a  nanocomposite).11
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Some  authors  state  that  the  main  difference  between  NPs
nd  ultraﬁne  particles  (UFP)  refers  to  the  fact  that  the  term
FP  is  commonly  used  to  describe  nanometer-size  particles
hat  have  not  been  intentionally  produced,  but  are  the  inci-
ental  products  of  industrial  processes  or  different  types  of
ombustion,  and  even  volcanic  activities.10
UFP  (or  incidental  nanoparticles)  show  more  complex
hemical  composition,  irregular  shapes,  and  polydispersed
ize  distribution  as  compared  to  engineered  particles.12
These  particles  could  exert  their  effects  per  se  or
hrough  a  multitude  of  substances  that  could  be  adsorbed
n  their  surfaces.  For  instance,  some  engineered  NPs  exist
s  nanocrystals  composed  of  a  number  of  compounds  such
s  silicon  and  metals  (quantum  dots).13
Carbon  fullerenes  represent  NPs  with  identical  dimen-
ions  in  all  directions  (i.e., spherical).  They  are  carbon
llotropes  rolled  up  to  form  closed-cage,  hollow  spheres.
ome  of  their  characteristics  such  as  their  small  size,  large
urface  area  and  high  reactivity  make  them  interesting  in
echnological  and  medical  ﬁelds.  They  were  initially  discov-
red  by  Kroto,  Smalley  and  Curl  (who  later  won  the  1996
obel  Prize  in  Chemistry)  as  a  new  form  of  carbon,  buck-
insterfullerene  or  C60.5,14,15
Single-walled  carbon  nanotubes  (SWCNTs)  typically  form
onvoluted,  ﬁbre-like  NPs  with  a  diameter  below  100  nm.
any  particle  morphologies  can  be  created  at  the  nanoscale,
ncluding  ‘‘ﬂower’’  and  ‘‘belt’’-like  structures.11
Multi-walled  carbon  nanotubes  (MWCNT)  are  larger  and
onsist  of  many  single-walled  tubes  stacked  one  inside  the
ther.16
Carbon  nanotubes  (CNTs)  are  distinct  from  carbon  ﬁbres,
ecause  the  latter  consist  of  strands  of  layered  graphite
heets  and  are  not  single  carbon  molecules.  CNTs  are
eported  to  be  physically  very  strong  and  stiff.  For  exam-
le  a  SWCNT  can  be  up  to  10  times  as  strong  as  steel  and
.2  times  as  stiff  as  diamond.16,17
Close-packed  nanotube  structures  could  have  a  yield
trength  exceeding  45  ±  7  GPa,  which  is  over  20  times  the
ield  strength  of  typical  high-strength  steels.17
As  would  be  expected  from  the  above  statements,  it  is
ow  understood  that  potential  occupational  and  environ-
ental  exposure  to  manufactured  NPs  is  on  the  increase.
anomedicine and the lung
he  ﬁeld  of  nanomedicine  is  the  science  and  technology  of
iagnosing,  treating  and  preventing  disease  and  traumatic
njury,  of  relieving  pain,  and  of  preserving  and  improv-
ng  human  health,  using  molecular  tools  and  molecular
nowledge  of  the  human  body.  Its  objectives  encom-
ass  monitoring,  control,  construction,  repair,  defense  and
mprovement  of  human  biological  systems,  using  engineered
evices  and  nanostructures  for  medical  beneﬁt.18
Nanomedicine  involves  the  best  knowledge  about  the
cience  and  technology  of  intricate  systems  of  nanometre-
cale  size,  with  several  components,  one  of  which  is  an
ctive  principle,  with  the  whole  system  leading  to  a  spe-
ial  function  connected  to  the  diagnosis,  treatment  and/or
revention  of  disease.18
Nanomedicine  also  includes  the  identiﬁcation  of
ew  molecular  targets,  the  creation  of  new  synthetic
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ow molecular  weight  drugs,  nanoﬂuidics  for  targeted
ynthesis,  nanodetection  for  target  identiﬁcation,  the
iscovery  of  natural  macromolecules,  including  anti-
odies,  proteins  and  genes  with  biological  activity  and
he  creation  of  drug  delivery  systems  (liposomes
nd  nanoparticles--nanopharmaceuticals),  promoting
isease-speciﬁc  targeting,  in  order  to  thoroughly  control
he  release  of  the  drugs  over  the  desired  period  of  time,  or
ven  to  supply  suitable  routes  of  administration  that  can
each  locations  in  the  body  that  are  traditionally  difﬁcult
o  access,  such  as  the  brain.18
Nanotechnology  has  an  enormous  potential  in  the  ﬁeld  of
uman  imaging  and  early  recognition  of  disease,  with  the
ailoring  of  speciﬁc  nanoagents  for  molecular  imaging  in
he  context  of  Magnetic  Resonance  Imaging,  ultrasound,
ptical  imaging,  and  X-ray  imaging.18--23
Other  medical  areas  include  gene  and  oncologic  ther-
py  using  multicomponent,  nanosized  delivery  vectors.
anotube  drug  delivery  is  promising  for  cancer  therapy
ith  high  treatment  efﬁcacy  and  minimum  side  effects.
here  is  an  increasing  use  of  NPs  as  carrier  systems  for
hemotherapeutic  drugs  because  of  the  ability  to  speciﬁcally
arget  cancer  cells,  improve  efﬁcacy  and  reduce  systemic
oxicity.24
Noble  metal  NPs  can  efﬁciently  target  several  kinds  of
umours,  as  they  present  highly  tunable  optical  properties
hat  can  be  adjusted  to  desirable  wavelengths  according  to
heir  shape  and  composition  with  possible  uses  in  tumour
argeting,  gene  silencing  and  drug  delivery;  they  can  also
fﬁciently  convert  light  or  radiofrequencies  into  heat,  pro-
oting  thermal  ablation.25
CNTs  can  be  effective  in  delivering  drugs  such  as  pacli-
axel  to  retard  tumour  growth  in  experimental  models  of
ancer.26,27
Solid  lipid  nanoparticles  (SLN)  are  ideal  carriers  for
eakly  soluble  drugs,  and  are  alternatives  to  current  col-
oidal  carriers.  Inhaled  SLN--paclitaxel  could  represent  a
otential  system  for  regional  delivery  to  the  lungs,  with  spe-
ial  efﬁcacy  on  the  lymphatic  system,  fundamental  in  the
rogression  of  lung  adenocarcinomas.28
Therefore,  targeted  nanoparticle  delivery  to  the  respi-
atory  system  is  one  of  the  future  trends  in  nanomedicine,
s  it  can  improve  drug  therapies  systemically  and  locally
sing  advanced  drug  delivery  systems  based  in  more  or  less
omplex  nanostructures.  In  the  speciﬁc  area  of  lung  can-
er  treatment,  NPs  can  revolutionize  future  chemotherapy
ptions.  Other  areas  of  development  are  the  improve-
ent  of  monoclonal  antibodies  for  lung  targeting  (attaching
ntibodies  to  drug  molecules  or  drug  delivery  systems),
ung  imaging,  gene  delivery,  cystic  ﬁbrosis  treatment  (gene
herapy  and  nano-selective  and  sustained  delivery  of  pro-
easome  inhibitor  drugs)  and  tuberculosis  diagnosis  and
reatment  (as  macrophage  involvement  make  NPs  a  perfect
rug  carrier).28--31
nvironmental challenges of exposure
o nanoparticlesoon  after  the  great  development  and  commercial  intro-
uction  of  these  materials,  some  authors  raised  signiﬁcant
uestions  about  the  potential  impact  on  human  health  and
he  environment.
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In  the  1990s,  toxicology  and  epidemiology  research  on
ultraﬁne  aerosols  began  developing  in  combination.  How-
ever,  the  emerging  ﬁeld  of  nanotechnology  stimulated  the
actions  toward  developing  a  more  complete  understanding
of  what  unexpected  and  unanticipated  impact  nanoscale
materials  might  have  on  health.12
In  recent  decades  there  has  been  human  exposure  to
nanoscale  particles  in  the  form  of  diesel  soot  and  bulk  UFPs
from  diverse  industrial  procedures,  essentially  in  the  form
of  combustion-derived  UFPs,  but  also  from  natural  sources
such  as  forest  ﬁres  and  volcanoes.
Exposure  to  these  particles  has  been  associated  with
pulmonary  inﬂammation,  immune  changes,  and  adverse
systemic  effects  including  blood  hypercoagulability,  con-
tributing  to  undesirable  cardiovascular  effects.32--35
Consistent  with  cross-sectional  ﬁndings  and  animal  stud-
ies,  there  seems  to  be  an  association  between  exposure  to
air  pollution  and  the  progression  of  atherosclerosis.36 Some
studies  report  the  association  of  particulate  matter  <2.5  um
(PM2.5)  and  carotid  intima-media  thickness.37
Oxidative  stress,  inﬂammation,  induction  of  a  pro-
coagulatory  state  and  dysfunction  of  the  autonomic  nervous
system  can  enhance  respiratory  and  cardiovascular  diseases.
Changes  in  lung  function,  heart  rate,  blood  pressure  and
inﬂammatory  state,  and  also  respiratory  symptoms,  throm-
bosis,  myocardial  infarction,  arrhythmia,  strokes,  and  death
are  more  often  seen  in  polluted  environments,  causing
shorter  life  expectancy.38
A  lot  of  the  concern  related  to  the  exposure  to  nano-
materials  comes  from  our  knowledge  from  the  reports  of
inhalation  of  ultraﬁne  particles  found  in  occupational  sett-
ings  and  also  ultraﬁne  aerosols  resulting  from  combustion.
There  seems  to  be  an  important  link  between  several  chronic
diseases  and  the  inhalation  of  UFPs,  such  as  Clara  cell  car-
cinomas  (polycyclic  aromatic  hydrocarbons),  mesothelioma
(asbestos),  and  berylliosis  (beryllium).  Some  syndromes
associated  with  exposure  to  aerosols  include  coal  worker
pneumoconiosis,  emphysema  (combustion  products),  and
metal  fume  fever  (zinc,  tin,  and  other  transition  metals).5
However,  the  technical  requirements  for  the  detection
and  characterization  of  nanoparticles  in  the  environ-
ment  push  the  limits  of  modern  sampling  techniques  and
instrumentation.5
At  present,  there  are  no  legal  thresholds  for  nanoparticle
number  concentrations  in  ambient  air,  so  local  observation
networks  do  not  generally  monitor  them.  The  development
of  ambient  particle  regulations  has  been  limited  for  tech-
nical  and  practical  reasons,  such  as  the  lack  of  standard
methods  and  instrumentation,  and  the  uncertainty  about
repeatability  and  reproducibility  of  measurements.39
Assessment  of  the  risk  associated  with  nanoparticles
requires  knowledge  about  the  ability  of  a  material  to  reach
a  sensitive  site  of  action,  and  the  type  and  magnitude  of  the
resultant  response  at  the  sensitive  site.5
NanotoxicologyThe  lung  is  the  primary  and  probably  the  most  important  tar-
get  of  nanomaterials,  but  NPs  can  enter  the  circulation  and
migrate  to  various  organs  and  tissues,  where  they  can  build
up  and  injure  organ  systems  that  are  sensitive  to  oxidative
a
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tress.  The  types  of  toxicological  response  will  probably  vary
etween  molecular  and  nano-sized  forms.
The  size  of  the  NPs  suggests  that  the  physiological
esponses  could  be  of  an  immune  or  inﬂammatory  nature.
hese  adverse  effects  may  not  follow  a  classic  dose-response
urve,  and  can  display  high  unpredictability  within  the  pop-
lation,  potentially  dependent  on  individual  sensitivity.5
Nanoparticle  toxicity  is  extremely  complex  and  multi-
actorial  and  depends  on  a  multiplicity  of  physicochemical
roperties  such  as  size  and  shape,  as  well  as  surface  prop-
rties  (charge,  area,  and  reactivity).  Ultraﬁne  or  nanosize
ange  (<100  nm)  particles  seem  to  be  more  toxic  on  a
ass-based  exposure  metric  compared  to  larger  particles
f  identical  chemical  composition.  Also,  particle  surface
rea  dose  is  a  better  predictor  of  the  toxic  and  pathological
esponses  to  inhaled  particles  than  particle  mass  dose.9,40
Differences  in  physico-chemical  properties  between  NPs
nd  larger  particles  determine  their  behaviour  as  aerosol,
heir  biodistribution  following  translocation  from  the  portal
f  entry,  their  cellular  interactions  and  effects.  Secondary
rgans  are  usually  affected  differently  from  the  primary  tar-
et  of  these  particles.27
In  1990,  the  Journal  of  Aerosol  Science  published  two
f  the  ﬁrst  cornerstone  papers  on  a  higher  than  expected
ffect  on  lung  inﬂammation  patterns  in  rats  exposed  to  NPs,
ffects  that  could  not  be  predicted  by  just  taking  the  chem-
cal  composition  and  the  inhaled  amounts  of  the  particles
nto  account.41--43
One  of  the  ﬁrst  important  assumptions,  that  is  still  of
reat  importance,  is  that  NPs  have  the  potential  to  show
reviously  unrecognized  biological  behaviour.43
A  major  report  concerning  the  uncertainties  of  nanotech-
ologies  was  published  in  2004  by  the  Royal  Society  and
he  Royal  Academy  of  Engineering.44 This  was  one  of  the
rst  reports  to  highlight  the  potential  risks  to  health  and
he  environment  that  may  arise  from  exposure  to  nanoma-
erials,  especially  NPs  (which  included  nanomaterials  such
s  nanotubes).  Since  then,  more  than  ﬁfty  national  and
nternational  reviews  carried  out  by  government  depart-
ents,  industry  associations,  insurance  organizations  and
esearchers  have  considered  nanoparticle  risk  issues.
A  workshop  co-sponsored  by  the  National  Science  Foun-
ation  and  the  US  Environmental  Protection  Agency  has
dentiﬁed  a  number  of  potential  risks  regarding  manufac-
ured  NPs,  such  as  exposure  assessment  of  manufactured
Ps;  toxicology  of  manufactured  NPs;  the  ability  (or  not)
o  extrapolate  manufactured  nanoparticle  toxicity  using
xisting  particle  and  ﬁbre  toxicological  databases;  envi-
onmental  and  biological  fate,  transport,  persistence,  and
ransformation  of  manufactured  NPs,  recyclability  and  over-
ll  sustainability  of  manufactured  nanomaterials.45
The  ability  of  absorbed  particles  to  generate  local  toxic
ffects  at  the  site  of  initial  deposition  as  well  as  very
igniﬁcant  systemic  toxic  responses  shows  how  dangerous
hey  can  be  in  real-life  settings.  The  potential  for  adverse
ealth  effects  may  arise  from  direct  exposure  to  intention-
lly  produced  nanomaterials  and/or  byproducts  associated
ith  their  applications.9Toxicological  assessment  of  manmade  nanomateri-
ls  requires  information  about  the  route  (inhalation,  oral,
ermal)  of  exposure,  as  well  as  their  complete  physicochem-
cal  characterization  of  them  in  order  to  provide  thorough
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nformation.  The  most  common  scenarios  for  human  expo-
ure  to  NPs  are  occupational,  environmental  and  consumer
nes.
nhalation hazards of nanoparticles
ne  of  the  most  widespread  routes  of  human  exposure  to
irborne  NPs  is  inhalation  in  the  workplace  and  the  environ-
ent.
As  seen  before,  at  present  there  are  large  numbers
f  nanomaterials;  as  their  technological  and  toxicological
roperties  vary  considerably,  so  will  their  risk  proﬁles.46 We
re  now  able  to  consider  that  the  extensive  and  heteroge-
eous  group  of  NPs  of  diverse  scale  constitutes  an  inhalation
azard  of  unknown  potential.
The  deposition  of  NPs  in  the  respiratory  tract  is
etermined  essentially  by  the  particle  aerodynamic  or  ther-
odynamic  diameter  (depending  on  particle  size).11
According  to  the  classical  model  developed  by  the  Inter-
ational  Commission  on  Radiological  Protection  (ICRP),  the
robability  of  nanoparticles  reaching  the  alveoli  peaked  at
 size  of  approximately  20  nm,  with  lower  probabilities  of
eposition  in  the  alveoli  for  both  smaller  and  larger  nano-
articles.  Nanoparticle  deposition,  in  particular  for  smaller
articles,  is  governed  by  Brownian  movements.12
There  are  still  issues  that  have  not  yet  been  fully  resolved
bout  how  exposure  to  NPs  can  be  thoroughly  measured  and
uantiﬁed;  they  are  usually  described  as  mass  concentration
units  mg  m−3);  number  concentration  (units  per  m−3) and
urface  area  concentration  units  (m2 m−3).
As  stated  before,  the  possible  health  effects  arising  from
xposure  to  NPs  may  be  better  correlated  with  surface  area,
ather  than  with  mass  concentration.6,16
NPs  have  some  essential  properties  that  could  be  directly
elated  to  their  pathogenicity:
 As  particles  less  than  100  nm,  they  may  have  more  toxicity
than  larger  sized  particles.
 Generally  they  are  considered  as  ﬁbre  shaped,  and  so
might  behave  like  some  other  pathogenic  ﬁbres  (asbestos,
man-made  ﬁbres).
 As  most  of  the  NPs  have  an  essentially  graphitic  constitu-
tion,  they  are  expected  to  be  biopersistent  in  biological
settings,  such  as  the  respiratory  system.16
Commercial  NPs  could  also  contain  some  impurities,  a
ommon  result  of  the  synthesis  process,  such  as  metals
Co,  Fe,  Ni,  and  Mo),  organic  compounds,  and  support
aterial.16
Smaller  particles  are  likely  to  be  more  aggressive  to  the
ung  than  larger  particles;  particles  with  more  inert  surfaces
ay  be  aggressive,  exerting  their  effects  on  cells  by  reason
f  having  a  large  surface  area.  Particles  with  more  reactive
urfaces  can  affect  cells  without  necessarily  having  large
urface  areas.16
Shape,  biopersistence,  presence  of  transition  metals  and
he  power  to  generate  reactive  oxygen  species  also  explain
he  potential  for  lung  damage.  In  fact,  some  of  the  main
xperimental  studies  in  rodents  and  cell  cultures  have  shown
hat  the  toxicity  of  UFPs  or  NPs  is  greater  than  that  of
he  same  mass  of  larger  particles  with  a  similar  chemical
s
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omposition,  posing  speciﬁcally  a  higher  respiratory  and  sys-
emic  health  threat.11
At  equivalent  mass  doses,  insoluble  ultraﬁne  particles
ause  more  damage  than  larger  particles  of  a  similar  compo-
ition  in  terms  of  pulmonary  inﬂammation,  tissue  damage,
nd  lung  tumours.11
From  the  alveoli,  NPs  have  the  potential  to  enter  the
loodstream  from  the  lungs  and  even  translocate  to  other
rgans.11 For  instance,  biokinetic  studies  show  that  inhaled
Ps  can  translocate  via  olfactory  neurons  from  the  nose  to
he  Central  Nervous  System.40
The  biokinetics  of  NPs  in  the  body  varies,  depending
n  the  portal  of  entry.  The  same  NPs  entering  the  lung
via  inhalation  or  intratracheal  instillation)  or  intravenously,
nteract  with  different  biological  media  and  will  receive
ifferent  secondary  coatings,  affecting  nanoparticle  biodis-
ribution  to  target  organs.27
At  present,  carrying  out  risk  assessment  of  NPs  can  only
e  done  sensibly  on  a  case-by-case  basis.6
Most  of  the  studies  about  the  effects  of  respiratory  expo-
ure  to  NPs  involve  pulmonary  models  and  are  performed
hrough  instillation,  aspiration  and  inhalation  of  carbon
anotubes  (the  most  studied  NPs)  in  rodent  species.
Table  1  summarizes  some  of  the  main  in  vivo  investiga-
ions  regarding  the  respiratory  effects  of  carbon  nanotubes.
Many  of  the  most  pressing  health  and  safety  concerns
egarding  NPs  and  nanotechnologies  come  from  the  lack  of
nowledge  about  levels  of  occupational  and  other  types  of
xposure  during  their  production  and  use.61
Among  the  particles  with  potential  respiratory  risks,  CNTs
re  one  of  the  specialized  structures  of  engineered  NPs  that
re  widespread.  Discovered  more  than  20  years  ago,  they
ave  increasing  potential  uses  in  biomedical,  aeronautic,
nd  industrial  ﬁelds  due  to  their  unique  conductive  and  elec-
rochemical  properties.59
As  seen  before,  CNTs  are  classiﬁed  according  to  their
tructure:  single-walled  carbon  nanotubes  (SWCNT)  and
ulti-walled  carbon  nanotubes  (MWCNT).
Nanotubes  can  have  features  of  both  NP  and  conventional
bres.  The  literature  currently  available  suggests  that  CNT
ay  have  toxic  effects  beyond  those  predictable  for  their
ass  exposure.  For  instance,  they  have  more  adverse  effects
han  the  same  mass  of  NP  carbon  and  quartz,  a  commonly
sed  comparator  amongst  harmful  inhalable  particles.16
CNTs  can  induce  oxidative  stress  and  inﬂammation,  and
everal  studies  imply  that  they  could  cause  granuloma  for-
ation  and  ﬁbrogenesis.16
In  occupational  contexts,  CNTs  should  be  considered  in
he  same  way  as  other  biopersistent  ﬁbres  in  the  workplace,
ith  implications  for  at  least  similar  approaches  to  control
nd  assessment.16
It  would  appear  that  the  main  mechanism  of  engineered
anomaterial  toxicity  is  related  to  oxidative  stress,  caused
y  the  activation  of  responsive  transcription  factors.  Chronic
nﬂammation  and  oxidative  stress  observed  during  and  after
xposure  can  induce  adverse  health  effects  such  as  ﬁbro-
is,  genotoxicity  and  cancer  caused  by  ﬁbres  or  secondary
utation.62One  of  the  ﬁrst  studies  on  the  subject  of  CNTs  expo-
ure  was  performed  by  Lam  et  al.48 In  this  study  mice
ere  instilled  intratracheally  with  0,  0.1,  or  0.5  mg  of
arbon  nanotubes,  a  carbon  black  negative  control,  or  a
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Table  1  In  vivo  investigations  of  carbon  nanotube  toxicity.
Animal  species,  agent  and
method  of  administration
Results  Authors
Intratracheal  instillation  of
CNT  containing  soot  on
guinea  pigs
No  induction  of  any  abnormalities  of  pulmonary  function  or
measurable  inﬂammation.  No  lung  pathology  was  performed
in this  study.
Huczko  et  al.
(2001)47
Intratracheal  instillation  of
different  SWCNT  samples
(three  SWCNT  products
made  by  different  methods
and  containing  different
types  and  amounts  of
residual  metals)  on  mice
All  nanotube  products  induced  dose-dependent  persistent
epithelioid  granulomas.  The  lungs  of  some  animals  also
revealed  peribronchial  inﬂammation  and  necrosis  extending
into the  alveolar  septa.  The  lungs  of  mice  treated  with  carbon
black  were  normal,  whereas  those  treated  with  high-dose
quartz  revealed  mild  to  moderate  inﬂammation.
Lam  e  al.  (2004)48
Intratracheal  instillation  of
SWCNT  on  Sprague-Dawley
rats
Pulmonary  exposures  to  SWCNT  in  rats  produced  a
non-dose-dependent  series  of  multifocal  granulomas,  which
were evidence  of  a  foreign  tissue  body  reaction  and  were  non
uniform in  distribution  and  not  progressive  beyond  1  month
post  exposure.
Warheit  et  al.
(2004)49
Intrapharyngeal  aspiration
of puriﬁed  SWCNT  on  mice
(C57CL/6)
Acute  inﬂammation,  early  onset  of  formation  of  granulomas,
and progressive  ﬁbrosis.  SWCNT-induced  granulomas,  mainly
associated  with  hypertrophied  epithelial  cells  surrounding  the
dust aggregates,  and  diffusive  interstitial  ﬁbrosis  and  alveolar
wall thickening.  Lung  lesions  were  dose-dependent  and
progressive.  Bronchial  alveolar  lavage  ﬂuid  (BALF)  increases
in total  protein  concentration,  cell  counts,  concentration
of transforming  growth  factor  beta  (TGF-),  lactate
dehydrogenase  (LDH),  and   -  glutamyltranspeptidase
activities,  and  glutathione  depletion  (biomarkers
of inﬂammation,  oxidative  stress,  and  cytotoxicity).
Shvedova  et  al.
(2005)50
Intratracheal  instillation  of
MWCNT  on  Sprague-Dawley
Rats
Inﬂammation,  collagen  rich  granulomas,  and  ﬁbrosis.
Hydroxyproline  and  soluble  collagen,  increased  in  the  lung
tissues  in  a  dose-dependent  fashion.
Muller  et  al.
(2005)51
Intrapharyngeal  instillation  of
SWCNT  on  mice  (C57CL/6)
Activation  of  heme-oxygenase-1  (HO-1),  a  marker  of  oxidative
insult,  in  lung,  aorta,  and  heart  tissue.  Aortic  mtDNA  damage
at 7,  28,  and  60  days  after  exposure.
Li  et  al.  (2007)52
Intratracheal
Instillation  +  inhalation  of
MWCNT  on  Kunming  mice
Difference  in  lung  pathological  lesions  induced  by  instilled  and
inhaled  MWCNTs  probably  due  to  different  size  and  distribution
of aggregations  of  MWCNTs  in  lung.
Li  et  al.  (2007)7
Whole-body  inhalation  of
MWCNT  on  mice  (C57CL/6)
The  experiment  did  not  result  in  signiﬁcant  lung  inﬂammation
or tissue  damage,  but  caused  systemic  immune  function
alterations.  BALF  demonstrated  particle-laden  macrophages.
Nonmonotonic  systemic  immunosuppression.  Decreased  NK  cell
function.  No  changes  in  gene  expression  were  observed  in  lung.
Mitchell  et  al.
(2007)53
Intratracheal  instillation
of  SWCNT  on  mice
Alveolar  macrophage  activation,  several  chronic  inﬂammatory
responses,  and  severe  pulmonary  granuloma  formation.
Chou  et  al.
(2008)54
Whole-body  inhalation  of
SWCNT  on  mice  (C57CL/6)
Development  of  multifocal  granulomatous  pneumonia
and interstitial  ﬁbrosis.  SWCNT  inhalation  caused  more
inﬂammatory  response,  oxidative  stress,  collagen  deposition,
ﬁbrosis and  mutations  of  K-ras  gene  when  compared  with
aspiration.
Shvedova  et  al.
(2008)55
Wistar  rats.  MWCNT--Acute
inhalation  study.  Positive
control:  alpha  quartz.
Negative  control:  air
Pulmonary  inﬂammogenicity  following  exposure  to  MWCNT  was
concentration-dependent  with  evidence  of  regression  over
time. Alpha-quartz  (positive  controls)  resulted  in  progressive
changes  over  time.
Ellinger-
Ziegelbauer  et  al.
(2009)56
Wistar  rats.  90-day  inhalation
toxicity  study  with  MWCNT
Pronounced  multifocal  granulomatous  inﬂammation,  diffuse
histiocytic  and  neutrophilic  inﬂammation,  and  intra-alveolar
lipoproteinosis  were  observed  in  lung  and  lung-associated
lymph  nodes,  incidence  and  severity  related.
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Table  1  (cont.)
Animal  species,  agent  and
method  of  administration
Results  Authors
Ma-Hock  et  al.  (2009)57
Wistar  rats.  MWCNT  --  Acute
inhalation  with  3  months
postexposure  period;
Repeated  inhalation
exposure  with  6  months
postexposure  period
Sustained  pulmonary  inﬂammation  related  to  pulmonary
overload  of  NPs  resulting  probably  from  stasis  of  clearance.
Macrophages  with  enlarged  and/or  foamy  appearance;
increased  inﬂux  of  inﬂammatory  cells  and  septal  thickening,
slight  to  moderate  inﬂammation,  focally  with  granulomatous
appearance;  interstitial  ﬁbrosis.  Thickening  of  the  visceral
pleura. Inﬂammation  did  not  decrease  in  severity  with
increasing  post-exposure  duration.
Pauluhn  (2010)58
C57BL/6  mice.  Repeated
pharyngeal  aspiration
of SWCNTs,  crocidolite,
and  ultraﬁne  carbon  black
The  incidence  and  severity  of  inﬂammatory  and  ﬁbrotic
responses  were  greatest  in  mice  treated  with  SWCNTs.  The
proteomic  analysis  suggested  that  lung  tissue  and  lung
inﬁltrate  responses  to  SWCNT  and  crocidolite  asbestos  were
similar,  but  as  for  several  histopathological  endpoints,  the
response  was  generally  greater  on  a  mass  dose  basis  for
SWCNT,  when  compared  with  asbestos  or  ultraﬁne  carbon
black.
Teeguarden  et  al.
(2010)59
SWCNT-transformed  cells
injected  in  immunodeﬁcient
One  week  post-injection,  tumours  were  formed  at  the
injection  site  in  mice  receiving  B-SWCNT  cells,  whereas  mice
2B  ce
Wang  et  al.
(2011)60
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smice receiving  control  BEAS-
uartz  positive  control,  and  lung  pathology  studied  7  or
0  days  after  exposure.  All  nanotube  products  induced
ose-dependent  epithelioid  granulomas  and,  in  some  cases,
nterstitial  inﬂammation,  which  was  more  pronounced  in  the
0-day  group.  Some  animals  had  peribronchial  inﬂammation
nd  necrosis,  extending  to  the  alveolar  septa.  On  a same
eight  basis,  when  CNTs  reach  the  lungs,  they  are  much
ore  toxic  than  carbon  black  and  can  be  more  toxic  than
uartz.48
Inhalation  studies  are  able  to  provide  more  information
nd  reproducibility  of  occupational  and  environmental  risks.
owever,  instillation  studies  are  less  complex  and  cheaper,
o  they  could  represent  a  form  of  screening  for  the  potential
arm  and  toxicity  of  NPs.62
In  the  experiments  where  intratracheal  instillation  of  NPs
as  performed,  more  pronounced  and  severe  effects  were
bserved,  when  compared  with  inhalation  studies.62,63
CNTs  have  toxicologically  signiﬁcant  structural  and
hemical  similarities  to  asbestos,  and  experiments  have
hown  that  they  cause  pulmonary  inﬂammation,  granuloma
ormation  and  ﬁbrosis  after  entering  the  respiratory  sys-
em  of  rodents,  as  observed  after  exposure  to  asbestos.
ome  studies  conﬁrm  for  MWCNTs  a  well  established
sbestos-like  pathogenicity  that  is  associated  with  long
bres.59,64
In  addition,  the  impact  of  some  impurities,  such  as
etals,  present  in  some  MWCNTs  cannot  be  underestimated
n  the  forms  in  which  the  lung  could  be  affected.65
According  to  Pacurari  et  al.,  the  ﬁbrous  characteristics  of
WCNT,  their  durability  and  their  ability  to  generate  reac-
ive  oxygen  species  at  low  levels  in  cellular  systems  may
ontribute  to  the  initiation  and  progression  of  asbestos-like
athological  responses.66
Shvedova  et  al.  demonstrated  that  SWCNT  inhalation
esulted  in  mutations  of  K-ras  gene  locus  in  the  lung  of
r
S
wlls  did  not  develop  tumours.
57BL/6  mice.  This  is  one  of  the  mutated  genes  that  can
e  implicated  in  pulmonary  tumourigenesis.55
Aerosolized  inhalation  in  animal  studies  supports  a  com-
on  sequence  of  biological  events  following  single  CNT
xposure:  important  acute  phase  inﬂammation  similar  to  a
oreign  body  response,  followed  by  formation  of  multifocal
ranulomas,  and  early  onset  ﬁbrosis.59
MWCNTs  and  other  carbon  NPs  in  ﬁne  (<2.5  m)  par-
iculate  matter  (PM)  aggregates  have  been  related  to  the
ombustion  of  methane,  propane,  and  natural-gas  ﬂames  of
ome  stoves;  indeed,  indoor  and  outdoor  ﬁne  PM  samples
ere  reported  to  contain  signiﬁcant  fractions  of  MWCNTs.
A  very  recent  study  from  Teeguarden  et  al.  used
igh  sensitivity  based  proteomics  -- HPLC--FTICR--MS  (high
erformance  liquid  chromatography/Fourier  transform  ion
yclotron  resonance  mass  spectrometry)  to  assess  some
f  the  major  differences  in  exposure  to  three  materials
-  SWCNT,  asbestos,  and  ultraﬁne  carbon  black  (UFCB).59
odent  exposure  to  SWCNT  led  to  a  signiﬁcantly  greater
nﬂammatory  response,  when  compared  with  crocidolite
sbestos  and  UFCB,  with  an  increase  in  polymorphonuclear
eutrophils  (PMNs)  and  total  cell  count  of  bronchoalveolar
avage  ﬂuid  (BALF).  Also,  moderate  multifocal  inﬂamma-
ion  was  present  in  all  lungs  from  SWCNT  exposed  mice,
ith  granuloma  formation  near  bronchioles  and  adjacent
lveoli  consisting  of  round  clusters  of  large  macrophages
nd  multinucleated  giant  cells.  Statistically  signiﬁcant  dif-
erences  in  some  cytokines  (TARC,  IL-12  and  MDC)  were  also
een,  proving  the  high  inﬂammogenic  potential  of  SWCNT.  In
ddition,  the  proteomic  analysis  conducted  by  the  authors
upports  the  conclusion  that  lung  tissue  and  lung  inﬁltrate
esponses  were  generally  greater  on  a  mass  dose  basis  for
WCNT.
The  potential  for  particles  to  cause  ﬁbrotic  reactions
ithin  the  lung  depends  on  the  particle  size,  composition,
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surface  activity,  and  retained  dose.  Particles  containing
certain  transition  metals  have  a  greater  capacity  to  gen-
erate  reactive  oxygen  species,  in  addition  to  those  already
generated  by  inﬂammatory  neutrophils  and  activated  alve-
olar  macrophages.58
Recently,  Wang  at  al.  demonstrated  that  chronic  expo-
sure  to  SWCNT  can  produce  malignant  transformation  of
human  lung  epithelial  cells.  Also,  SWCNT-transformed  cells
injected  in  immunodeﬁcient  mice  led  to  tumour  growth
at  the  injection  site  in  mice  receiving  SWCNT-transformed
BEAS-2B  cells,  whereas  mice  receiving  control  BEAS-2B  cells
did  not  develop  tumours,  showing  also  the  potential  role  of
p53  in  this  process.60
Like  other  areas  of  knowledge  regarding  nanotech-
nologies,  studies  of  the  carcinogenic  potential  of  carbon
nanotubes  are  still  in  the  early  stages,  but  there  are  some
data  suggesting  that  these  structures  are  not  risk  free,  and
can  be  widely  dependent  on  several  other  physico-chemical
and  biological  characteristics,  and  also  speciﬁc  composition
and  type  and  size  of  impurities.3
Also,  fullerenes  (NPs  with  identical  dimensions  in  all
directions)  following  exposure  via  the  pulmonary  route  are
capable  of  eliciting  localized  responses  that  are  pro-  or  anti-
inﬂammatory  in  nature,  with  the  type  of  response  initiated
likely  to  be  reliant  on  the  fullerene  in  question,  exposure
method  and  the  dose  used.  However,  inhalation  studies
regarding  the  effects  of  fullerenes  are  still  limited.6
Fullerene  toxicity  probably  involves  an  oxidant  response,
suggesting  the  potential  of  fullerenes  to  cause  oxidative
stress  and  related  consequences  (such  as  inﬂammation  or
genotoxicity).  Generally,  the  greater  the  water  solubility
exhibited  by  a  fullerene  sample,  the  lower  the  toxicity  asso-
ciated  with  exposure.6
In  addition,  recent  studies  in  murine  models  prove  that
titanium  dioxide  (TiO2)  or  gold  (Au)  NPs  can  interfere  with
the  modulation  of  the  asthmatic  response  regarding  diiso-
cyanate  induced  asthma,  as  they  can  aggravate  pulmonary
inﬂammation  and  airway  hyperreactivity.67
There  is  still  a  shortage  of  publications  addressing  the
in  vivo, real  world  effects  of  nanoparticle  exposure.  How-
ever,  some  of  these  are  very  worrying;  for  instance,  Chinese
workers  exposed  to  polyacrylate  consisting  of  NPs  in  a  print
plant  have  shown  shortness  of  breath,  and  the  same  clin-
ical  ﬁndings  of  pleural  effusion  and  pericardial  effusion.
The  study  of  these  workers  revealed  nonspeciﬁc  pulmonary
inﬂammation,  pulmonary  ﬁbrosis  and  foreign-body  granu-
lomas  of  the  pleura;  BALF  elicited  increased  lymphocytes
and  neutrophil  leukocytes.  Two  young  patients  subsequently
died  from  respiratory  failure.68
Conclusions and future trends
Respiratory  exposure  to  NPs  can  cause  important  adverse
respiratory  effects,  such  as  multifocal  granulomas,  peri-
bronchial  inﬂammation,  progressive  interstitial  ﬁbrosis,
chronic  inﬂammatory  responses,  collagen  deposition,  oxida-
tive  stress,  pleural  lesions  and  gene  mutations,  at  least  in
experimental  animal  studies.At  this  point  in  time,  it  is  fundamental  to  know  more
about  the  toxicological  effects  of  NPs,  to  address  the
increased  concern  of  potentially  harmful  public  and  occu-
pational  exposures.27
P
d
a35
A  very  wide  range  of  endpoints  have  to  be  considered
hen  testing  potential  risks  derived  from  NPs.  Hazards
hould  be  tested  according  to  their  potential  routes  within
he  human  body.
According  to  Oberdörster  in  a  recent  paper  regarding
he  safety  assessment  for  nanotechnology,  although  many
f  the  current  engineered  nanomaterials  with  a  potential  for
uman  exposure  are  not  likely  to  induce  signiﬁcant  adverse
ffects,  some  could  cause  an  asbestos-type  disaster  if  it  is
ot  controlled.27
There  is,  therefore,  an  urgent  need  for  the  development
f  criteria  for  extrapolating  toxicological  data  in  biological
ystems  in  order  to  predict  the  risk  of  adverse  outcomes  in
umans.65
Not  only  traditional  tests,  but  also  newer  models  reﬂect-
ng  the  permanent  evolution  of  nanotoxicology  as  an
merging  ﬁeld,  should  be  used  to  shed  light  on  the  mech-
nisms  of  NP  toxicity.  The  combination  of  in  vitro  and
n  vivo  tests  should  contribute  to  hazard  assessment  in  the
uture.  A  multidisciplinary  team  approach  is  fundamental  to
ddressing  respiratory  human  risks  related  with  Nanotech-
ology.
At  present,  there  are  several  extremely  relevant
ttempts  currently  under  way  in  order  to  formulate
 science-based  risk  management  research  framework.
ne  of  them  is  the  US.  National  Nanotechnology  Initia-
ive/Environmental,  Health,  and  Safety  Research  Strategy;
he  main  research  needs  to  include,  among  other  points,  the
evelopment  of  measurement  tools  for  the  determination
f  physico-chemical  properties  of  engineered  nanomate-
ials  (ENMs),  their  detection  and  monitoring  in  realistic
xposure  media  and  conditions  during  the  life  cycle,  the
valuation  of  transformations  of  ENMs  in  relevant  media,
he  further  assessment  of  biological  responses,  the  better
nderstanding  of  the  processes  and  factors  that  determine
xposures  to  nanomaterials,  the  identiﬁcation  of  popula-
ion  groups  exposed  to  ENMs  and  their  health  surveillance,
nd  the  development  of  appropriate,  reliable,  and  repro-
ucible  assays  and  models  to  predict  human  responses  to
NMs.
With  appropriate  strategies  that  integrate  risk  assess-
ent  into  decision-making  frameworks  for  risk  manage-
ent,  and  incorporate  and  standardize  risk  communication
ithin  the  risk  management  framework,  better  esults  should
e  expected  in  the  future.2
Now  is  the  time  to  promote,  on  a global  scale,  an  in-depth
iscussion  and  evaluation  of  the  human  and  environmental
isks  of  these  new  materials;  as  stated  by  Maynard  et  al.,43
hese  resources  are  ‘‘merely  the  vanguard  of  a new  era  of
omplex  materials,  where  novel  and  dynamic  functional-
ty  is  engineered  into  multifaceted  substances.  If  we  are  to
eet  the  challenge  of  ensuring  the  safe  use  of  this  new  gen-
ration  of  substances,  it  is  time  to  move  beyond  ‘‘nano’’
oxicology  and  toward  a  new  toxicology  of  sophisticated
aterials.’’rotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  investigation.
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onﬁdentiality  of  data.  The  authors  declare  that  no  patient
ata  appears  in  this  article.
ight  to  privacy  and  informed  consent.  The  authors
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